 Lisa Brents
Concepts (176)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Naphthalenes | 9 | 2015 | 121 | 1.700 |
Why?
| | Neonatal Abstinence Syndrome | 2 | 2023 | 25 | 1.610 |
Why?
| | Indoles | 10 | 2015 | 278 | 1.600 |
Why?
| | Buprenorphine | 2 | 2023 | 140 | 1.350 |
Why?
| | Receptor, Cannabinoid, CB1 | 9 | 2015 | 125 | 1.340 |
Why?
| | Personality Disorders | 2 | 2018 | 20 | 1.140 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 381 | 1.130 |
Why?
| | Aromatase | 1 | 2023 | 8 | 0.930 |
Why?
| | Cannabinoids | 3 | 2013 | 105 | 0.850 |
Why?
| | Substance-Related Disorders | 2 | 2022 | 600 | 0.840 |
Why?
| | Mitragyna | 1 | 2022 | 9 | 0.830 |
Why?
| | Analgesics, Opioid | 3 | 2023 | 552 | 0.800 |
Why?
| | Morphine | 2 | 2024 | 103 | 0.790 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2024 | 186 | 0.770 |
Why?
| | Behavioral Research | 1 | 2021 | 3 | 0.770 |
Why?
| | Narcotics | 1 | 2021 | 111 | 0.720 |
Why?
| | Personality | 1 | 2018 | 27 | 0.630 |
Why?
| | Adult Survivors of Child Abuse | 1 | 2018 | 20 | 0.630 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2019 | 169 | 0.620 |
Why?
| | Fetus | 1 | 2019 | 217 | 0.600 |
Why?
| | Cocaine-Related Disorders | 2 | 2018 | 205 | 0.560 |
Why?
| | Endocannabinoids | 1 | 2016 | 23 | 0.550 |
Why?
| | Pregnancy | 5 | 2024 | 2607 | 0.510 |
Why?
| | Receptors, Cannabinoid | 2 | 2012 | 19 | 0.500 |
Why?
| | Animals | 17 | 2024 | 13187 | 0.470 |
Why?
| | Rats | 5 | 2024 | 3305 | 0.460 |
Why?
| | Child Abuse | 1 | 2015 | 136 | 0.430 |
Why?
| | Stress, Psychological | 1 | 2015 | 260 | 0.430 |
Why?
| | Rats, Long-Evans | 2 | 2023 | 26 | 0.420 |
Why?
| | Hemiterpenes | 1 | 2011 | 10 | 0.400 |
Why?
| | Metabolic Detoxication, Phase I | 1 | 2011 | 11 | 0.390 |
Why?
| | Glucuronosyltransferase | 2 | 2012 | 126 | 0.390 |
Why?
| | Plant Extracts | 1 | 2013 | 190 | 0.380 |
Why?
| | Stilbenes | 1 | 2011 | 62 | 0.380 |
Why?
| | Behavior, Animal | 1 | 2012 | 181 | 0.370 |
Why?
| | Pain | 1 | 2013 | 379 | 0.360 |
Why?
| | Receptors, Opioid, mu | 3 | 2023 | 46 | 0.350 |
Why?
| | Body Temperature | 4 | 2015 | 69 | 0.340 |
Why?
| | Female | 10 | 2024 | 26472 | 0.340 |
Why?
| | Binding, Competitive | 4 | 2013 | 94 | 0.340 |
Why?
| | Animals, Newborn | 2 | 2021 | 367 | 0.330 |
Why?
| | Infant, Newborn | 2 | 2023 | 2772 | 0.270 |
Why?
| | Humans | 17 | 2023 | 49974 | 0.260 |
Why?
| | Hydroxylation | 4 | 2012 | 61 | 0.250 |
Why?
| | Hypothermia | 2 | 2015 | 35 | 0.240 |
Why?
| | Receptor, Cannabinoid, CB2 | 3 | 2013 | 58 | 0.230 |
Why?
| | Mice | 9 | 2015 | 5739 | 0.230 |
Why?
| | Male | 8 | 2024 | 25241 | 0.210 |
Why?
| | Placenta | 1 | 2023 | 132 | 0.210 |
Why?
| | Alcohol Drinking | 1 | 2024 | 224 | 0.210 |
Why?
| | Motor Activity | 2 | 2015 | 229 | 0.200 |
Why?
| | United States Food and Drug Administration | 1 | 2022 | 93 | 0.200 |
Why?
| | Ethanol | 1 | 2024 | 340 | 0.190 |
Why?
| | Pain Management | 1 | 2022 | 160 | 0.190 |
Why?
| | Automation | 1 | 2021 | 17 | 0.190 |
Why?
| | Video Recording | 1 | 2021 | 79 | 0.180 |
Why?
| | Movement | 1 | 2021 | 82 | 0.180 |
Why?
| | ROC Curve | 1 | 2021 | 232 | 0.180 |
Why?
| | Brain | 4 | 2024 | 1328 | 0.180 |
Why?
| | Cricetinae | 4 | 2013 | 192 | 0.180 |
Why?
| | Molecular Structure | 4 | 2013 | 297 | 0.170 |
Why?
| | Sensitivity and Specificity | 1 | 2021 | 861 | 0.160 |
Why?
| | Software | 1 | 2021 | 273 | 0.160 |
Why?
| | Risk | 1 | 2019 | 320 | 0.160 |
Why?
| | CHO Cells | 3 | 2013 | 120 | 0.150 |
Why?
| | Ligands | 3 | 2013 | 204 | 0.150 |
Why?
| | Young Adult | 2 | 2018 | 3958 | 0.140 |
Why?
| | Menstrual Cycle | 1 | 2016 | 6 | 0.140 |
Why?
| | Progesterone | 1 | 2016 | 57 | 0.140 |
Why?
| | Fertility | 1 | 2016 | 28 | 0.140 |
Why?
| | Kinetics | 3 | 2012 | 623 | 0.140 |
Why?
| | Pentacyclic Triterpenes | 2 | 2012 | 8 | 0.130 |
Why?
| | Protein Binding | 3 | 2013 | 660 | 0.130 |
Why?
| | Drug Tolerance | 1 | 2015 | 60 | 0.130 |
Why?
| | Personality Assessment | 1 | 2015 | 13 | 0.130 |
Why?
| | Mice, Inbred Strains | 2 | 2012 | 161 | 0.120 |
Why?
| | Rats, Sprague-Dawley | 2 | 2024 | 1597 | 0.120 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2012 | 195 | 0.120 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 280 | 0.120 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2015 | 319 | 0.110 |
Why?
| | Cyclohexanols | 1 | 2013 | 21 | 0.110 |
Why?
| | Analysis of Variance | 1 | 2015 | 562 | 0.110 |
Why?
| | Membranes | 1 | 2013 | 17 | 0.110 |
Why?
| | Mass Spectrometry | 2 | 2012 | 306 | 0.110 |
Why?
| | Cannabis | 1 | 2016 | 145 | 0.110 |
Why?
| | Recombinant Proteins | 2 | 2012 | 486 | 0.110 |
Why?
| | Drug Synergism | 1 | 2013 | 150 | 0.110 |
Why?
| | Anticarcinogenic Agents | 1 | 2012 | 34 | 0.110 |
Why?
| | Drug Interactions | 1 | 2013 | 206 | 0.110 |
Why?
| | Psychomotor Performance | 1 | 2013 | 130 | 0.110 |
Why?
| | Quinuclidines | 1 | 2013 | 40 | 0.110 |
Why?
| | Conditioning, Operant | 1 | 2013 | 116 | 0.100 |
Why?
| | YY1 Transcription Factor | 1 | 2012 | 7 | 0.100 |
Why?
| | Triterpenes | 1 | 2012 | 11 | 0.100 |
Why?
| | Pain Measurement | 1 | 2013 | 240 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 903 | 0.100 |
Why?
| | Drug Partial Agonism | 1 | 2012 | 6 | 0.100 |
Why?
| | Drug Antagonism | 1 | 2012 | 7 | 0.100 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2012 | 16 | 0.100 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2012 | 49 | 0.100 |
Why?
| | Isoproterenol | 1 | 2012 | 56 | 0.100 |
Why?
| | Adrenergic beta-Agonists | 1 | 2012 | 39 | 0.100 |
Why?
| | Receptor, erbB-2 | 1 | 2012 | 73 | 0.100 |
Why?
| | Prenylation | 1 | 2011 | 3 | 0.100 |
Why?
| | Metabolic Detoxication, Phase II | 1 | 2011 | 11 | 0.100 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2012 | 69 | 0.100 |
Why?
| | GTP-Binding Proteins | 1 | 2012 | 90 | 0.100 |
Why?
| | Middle Aged | 2 | 2018 | 12069 | 0.100 |
Why?
| | Piperidines | 1 | 2012 | 98 | 0.100 |
Why?
| | United States | 1 | 2022 | 4860 | 0.100 |
Why?
| | Narcotic Antagonists | 1 | 2012 | 135 | 0.100 |
Why?
| | Pyrazoles | 1 | 2012 | 113 | 0.100 |
Why?
| | Biological Availability | 1 | 2011 | 122 | 0.100 |
Why?
| | Protein Transport | 1 | 2012 | 180 | 0.100 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2012 | 117 | 0.100 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 181 | 0.100 |
Why?
| | Repressor Proteins | 1 | 2012 | 151 | 0.090 |
Why?
| | Adult | 2 | 2018 | 13236 | 0.090 |
Why?
| | Cell Membrane | 1 | 2012 | 248 | 0.090 |
Why?
| | Down-Regulation | 1 | 2012 | 348 | 0.090 |
Why?
| | Models, Molecular | 1 | 2011 | 338 | 0.090 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2011 | 349 | 0.090 |
Why?
| | Plaque, Amyloid | 1 | 2010 | 15 | 0.090 |
Why?
| | Extracellular Space | 1 | 2010 | 38 | 0.090 |
Why?
| | Chondroitin Sulfate Proteoglycans | 1 | 2010 | 18 | 0.090 |
Why?
| | Amyloid beta-Protein Precursor | 1 | 2010 | 23 | 0.090 |
Why?
| | Lectins, C-Type | 1 | 2010 | 30 | 0.090 |
Why?
| | Risk Factors | 1 | 2018 | 3613 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 1376 | 0.090 |
Why?
| | Cells, Cultured | 1 | 2013 | 1573 | 0.090 |
Why?
| | Protein Processing, Post-Translational | 1 | 2010 | 171 | 0.080 |
Why?
| | MicroRNAs | 1 | 2012 | 353 | 0.080 |
Why?
| | Nerve Tissue Proteins | 1 | 2010 | 193 | 0.080 |
Why?
| | Receptors, Adrenergic, alpha-2 | 1 | 2024 | 8 | 0.060 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2024 | 15 | 0.060 |
Why?
| | Adolescent | 1 | 2015 | 6356 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2012 | 1174 | 0.050 |
Why?
| | Neoplasms | 1 | 2012 | 1235 | 0.050 |
Why?
| | Injections, Intraperitoneal | 1 | 2014 | 54 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2014 | 107 | 0.030 |
Why?
| | Stereoisomerism | 1 | 2013 | 104 | 0.030 |
Why?
| | Psychotropic Drugs | 1 | 2013 | 77 | 0.030 |
Why?
| | Drug Inverse Agonism | 1 | 2012 | 18 | 0.030 |
Why?
| | Sp Transcription Factors | 1 | 2012 | 6 | 0.030 |
Why?
| | Pyrans | 1 | 2012 | 22 | 0.030 |
Why?
| | Cytochrome P-450 CYP1A2 | 1 | 2012 | 39 | 0.030 |
Why?
| | Cricetulus | 1 | 2012 | 97 | 0.030 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 74 | 0.030 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2012 | 4 | 0.030 |
Why?
| | Glucuronides | 1 | 2012 | 45 | 0.030 |
Why?
| | Morpholines | 1 | 2012 | 71 | 0.030 |
Why?
| | rab GTP-Binding Proteins | 1 | 2012 | 35 | 0.020 |
Why?
| | Mice, Nude | 1 | 2012 | 252 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2012 | 90 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2012 | 119 | 0.020 |
Why?
| | Microsomes, Liver | 1 | 2012 | 186 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2012 | 322 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2012 | 222 | 0.020 |
Why?
| | Brevican | 1 | 2010 | 8 | 0.020 |
Why?
| | Chondroitin Sulfates | 1 | 2010 | 13 | 0.020 |
Why?
| | Brain Chemistry | 1 | 2010 | 70 | 0.020 |
Why?
| | Culture Media | 1 | 2010 | 94 | 0.020 |
Why?
| | Neurons | 1 | 2012 | 460 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2010 | 242 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 601 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 595 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2010 | 555 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 976 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2012 | 1007 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2012 | 828 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 1403 | 0.020 |
Why?
| | Cell Line | 1 | 2010 | 1000 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2010 | 973 | 0.020 |
Why?
| | Apoptosis | 1 | 2012 | 1101 | 0.020 |
Why?
| | Liver | 1 | 2012 | 1115 | 0.020 |
Why?
| | Alzheimer Disease | 1 | 2010 | 324 | 0.020 |
Why?
|
|
Brents's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|